Market capitalization | $50.94m |
Enterprise Value | $-2.92m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.11 |
EV/Sales (TTM) EV/Sales | -0.09 |
P/S ratio (TTM) P/S ratio | 1.60 |
P/B ratio (TTM) P/B ratio | 0.91 |
Revenue (TTM) Revenue | $31.91m |
EBIT (operating result TTM) EBIT | $-9.74m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
1 Analyst has issued a forecast Enzo Biochem, Inc.:
1 Analyst has issued a forecast Enzo Biochem, Inc.:
Jul '24 |
+/-
%
|
||
Revenue | 32 32 |
-
|
|
Gross Profit | 15 15 |
-
|
|
EBITDA | -8.46 -8.46 |
-
|
EBIT (Operating Income) EBIT | -9.74 -9.74 |
-
|
Net Profit | -26 -26 |
-
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Enzo Biochem, Inc. engages in the development, manufacture and sale of technology solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians globally. It operates through the following segments: Enzo Clinical Laboratory Services, Enzo Life Sciences Products, and Enzo Therapeutics. The Enzo Clinical Laboratory Services segment includes clinical reference laboratory providing a wide range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. The Enzo Life Sciences Products segment manufactures, develops and markets products and tools for clinical research, drug development and bioscience research customers worldwide. The Enzo Therapeutics segment develops multiple novel approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, many of which are derived from the pioneering work of Enzo Life Sciences. The company was founded by Elazar Rabbani, Barry W. Weiner and Shahram K. Rabbani in 1976 and is headquartered in New York, NY.
Head office | United States |
CEO | Kara Cannon |
Employees | 136 |
Founded | 1976 |
Website | www.enzo.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.